A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma
Clinical Trial Grant
Awarded By
Merck Sharp & Dohme
Start Date
June 13, 2024
End Date
June 14, 2029
Awarded By
Merck Sharp & Dohme
Start Date
June 13, 2024
End Date
June 14, 2029